Clinical Trial Update: TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants [Phase 3]

View source ↗

Summary

Phase 3 trial update noting continued access to etravirine for treatment-experienced HIV-1 infected participants, with results posted in December 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (Etravirine)

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: HIV Infections, HIV-1 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-21